Wedo Venture Partners
VC Fund
Singapore, Singapore
Wedo Venture Partners is a VC fund in Singapore focused on Biotechnology and Medical. Wedo Venture Partners bridges science, culture, and venture capital from East and West to unlock human health, empowering the next generation of global biotech and medtech leaders.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Wedo Venture Partners invests in
Stages Wedo Venture Partners invests in
Countries Wedo Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Xinhong Lim
|
|||
Investment Focus
Industry
- Biotechnology 7 (50%)
- Medical 4 (29%)
- Therapeutics 3 (21%)
- Pharmaceutical 3 (21%)
- Biopharma 2 (14%)
Stage
- Series A 7 (50%)
- Series B 3 (21%)
- Seed 2 (14%)
- Series C 1 (7%)
- Series D 1 (7%)
Country
- China 10 (71%)
- United States 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Xinhong Lim
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Drug Farm
|
Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. | $55M / Series D / Jul 13, 2026 | |
HemaCell
|
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish aplatform using platelet cells as a drug delivery carrier. | $14.8M / Series B / Jun 02, 2026 | |
Next Generation Gene Therapeutics
|
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world.NGGT was founded in March 2020by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products. | $40M / Series B / Jul 11, 2023 | |
|
Drug Farm
|
Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. | $27M / Series C / May 16, 2023 | |
Iridium Molybdenum Intelligent
|
Iridium Molybdenum Intelligent engages in creating intelligent construction machinery products and providing integrated solutions for mine capacity services. | $16M / Series A / Mar 22, 2023 | |
Qihui Biotechnology
|
Qihui Biotechnology is a research and development company of testing and diagnostic equipment. | Series A / Dec 06, 2022 | |
Huixin Bio
|
Huixin Bio is a developer of exosome purification products and early cancer detection technology. | Seed / Aug 16, 2022 | |
|
HemaCell
|
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish aplatform using platelet cells as a drug delivery carrier. | Series A / May 27, 2022 | |
Doctor AI Yisheng Intelligence
|
Doctor AI is a med-tech firm that provides a smart AI medical record quality control system. | Series A / Dec 28, 2021 | |
Geneus
|
Geneus is a developer of gene sequencers and reagents. | Series B / Sep 28, 2021 | |
| See all 14 investments → | |||
Co-Investors
WeDo Capital Management
10 deals together
DT Capital Partners
3 deals together
Northern Light Venture Capital
3 deals together
Shanghai Biomedical Industrial Equity Investment Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Wedo Venture Partners invest in?
Wedo Venture Partners invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wedo Venture Partners?
Public channels for Wedo Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wedo Venture Partners?
The team at Wedo Venture Partners includes Xinhong Lim (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
